Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study
Background/Aims The combination of daclatasvir (DCV) and asunaprevir (ASV) has demonstrated a high sustained virologic response at 12 weeks (SVR12) and a low rate of adverse events in previous clinical studies. The purpose of this study was to clarify the results of treatment and side effects in Kor...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Association for the Study of the Liver
2017-03-01
|
Series: | Clinical and Molecular Hepatology |
Subjects: | |
Online Access: | http://e-cmh.org/upload/pdf/cmh-2016-0053.pdf |
id |
doaj-84f303a2fb1349249c2ff5819abea564 |
---|---|
record_format |
Article |
spelling |
doaj-84f303a2fb1349249c2ff5819abea5642020-11-25T00:37:05ZengKorean Association for the Study of the LiverClinical and Molecular Hepatology2287-27282287-285X2017-03-01231515610.3350/cmh.2016.00531343Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional studyByeong Wook Cho0Seok Bae Kim1Il Han Song2Sae Hwan Lee3Hong Soo Kim4Tae Hee Lee5Young Woo Kang6Seok Hyun Kim7Byung Seok Lee8Hee Bok Chae9 Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea Department of Internal Medicine, Soonchunhyang University College of Medicine, Cheonan, Korea Department of Internal Medicine, Soonchunhyang University College of Medicine, Cheonan, Korea Department of Internal Medicine, Konyang University College of Medicine, Daejeon, Korea Department of Internal Medicine, Konyang University College of Medicine, Daejeon, Korea Department of Internal Medicine, Chungnam University College of Medicine, Daejeon, Korea Department of Internal Medicine, Chungnam University College of Medicine, Daejeon, Korea Department of Internal Medicine, Chungbuk University College of Medicine, Cheongju, KoreaBackground/Aims The combination of daclatasvir (DCV) and asunaprevir (ASV) has demonstrated a high sustained virologic response at 12 weeks (SVR12) and a low rate of adverse events in previous clinical studies. The purpose of this study was to clarify the results of treatment and side effects in Korean patients with chronic hepatitis C virus (HCV) genotype Ib infection. Methods We retrospectively analyzed clinical data from chronic HCV genotype Ib patients treated with DCV+ASV from August 2015 to September 2016 at five hospitals in the Daejeon-Chungcheong area. Results A total of 152 patients were examined for resistance associated variants (RAVs). Among them, 15 (9.9%) were positive for Y93 and one (0.7%) was positive for L31. Of 126 patients treated with DCV+ASV, 83 patients completed treatment and 76 patients were included in safety and efficacy analysis. Five (6.6%) were positive for Y93 and 12 (15.8%) exhibited cirrhotic change. DCV+ASV was the first-line treatment for 58 (76.3%) patients. Eleven (14.5%) patients relapsed after previous treatment that included interferon and seven (9.2%) of these patients were found to be intolerant of interferon. Adverse events occurred in 10 (13.2%) patients and two patients stopped the medication because of severe itching and skin rash. SVR12 was 89.5% (68/76) in all patients and 91.5% (65/71) in RAV-negative patients. Conclusions DCV+ASV showed good efficacy in patients with HCV Ib infection in Korea. Close monitoring is needed for severe adverse events and treatment failure, which were uncommon.http://e-cmh.org/upload/pdf/cmh-2016-0053.pdfDaclatasvirAsunaprevirHepatitis C, ChronicKorea |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Byeong Wook Cho Seok Bae Kim Il Han Song Sae Hwan Lee Hong Soo Kim Tae Hee Lee Young Woo Kang Seok Hyun Kim Byung Seok Lee Hee Bok Chae |
spellingShingle |
Byeong Wook Cho Seok Bae Kim Il Han Song Sae Hwan Lee Hong Soo Kim Tae Hee Lee Young Woo Kang Seok Hyun Kim Byung Seok Lee Hee Bok Chae Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study Clinical and Molecular Hepatology Daclatasvir Asunaprevir Hepatitis C, Chronic Korea |
author_facet |
Byeong Wook Cho Seok Bae Kim Il Han Song Sae Hwan Lee Hong Soo Kim Tae Hee Lee Young Woo Kang Seok Hyun Kim Byung Seok Lee Hee Bok Chae |
author_sort |
Byeong Wook Cho |
title |
Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study |
title_short |
Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study |
title_full |
Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study |
title_fullStr |
Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study |
title_full_unstemmed |
Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study |
title_sort |
efficacy and safety of daclatasvir plus asunaprevir for korean patients with hcv genotype ib infection: a retrospective multi-institutional study |
publisher |
Korean Association for the Study of the Liver |
series |
Clinical and Molecular Hepatology |
issn |
2287-2728 2287-285X |
publishDate |
2017-03-01 |
description |
Background/Aims The combination of daclatasvir (DCV) and asunaprevir (ASV) has demonstrated a high sustained virologic response at 12 weeks (SVR12) and a low rate of adverse events in previous clinical studies. The purpose of this study was to clarify the results of treatment and side effects in Korean patients with chronic hepatitis C virus (HCV) genotype Ib infection. Methods We retrospectively analyzed clinical data from chronic HCV genotype Ib patients treated with DCV+ASV from August 2015 to September 2016 at five hospitals in the Daejeon-Chungcheong area. Results A total of 152 patients were examined for resistance associated variants (RAVs). Among them, 15 (9.9%) were positive for Y93 and one (0.7%) was positive for L31. Of 126 patients treated with DCV+ASV, 83 patients completed treatment and 76 patients were included in safety and efficacy analysis. Five (6.6%) were positive for Y93 and 12 (15.8%) exhibited cirrhotic change. DCV+ASV was the first-line treatment for 58 (76.3%) patients. Eleven (14.5%) patients relapsed after previous treatment that included interferon and seven (9.2%) of these patients were found to be intolerant of interferon. Adverse events occurred in 10 (13.2%) patients and two patients stopped the medication because of severe itching and skin rash. SVR12 was 89.5% (68/76) in all patients and 91.5% (65/71) in RAV-negative patients. Conclusions DCV+ASV showed good efficacy in patients with HCV Ib infection in Korea. Close monitoring is needed for severe adverse events and treatment failure, which were uncommon. |
topic |
Daclatasvir Asunaprevir Hepatitis C, Chronic Korea |
url |
http://e-cmh.org/upload/pdf/cmh-2016-0053.pdf |
work_keys_str_mv |
AT byeongwookcho efficacyandsafetyofdaclatasvirplusasunaprevirforkoreanpatientswithhcvgenotypeibinfectionaretrospectivemultiinstitutionalstudy AT seokbaekim efficacyandsafetyofdaclatasvirplusasunaprevirforkoreanpatientswithhcvgenotypeibinfectionaretrospectivemultiinstitutionalstudy AT ilhansong efficacyandsafetyofdaclatasvirplusasunaprevirforkoreanpatientswithhcvgenotypeibinfectionaretrospectivemultiinstitutionalstudy AT saehwanlee efficacyandsafetyofdaclatasvirplusasunaprevirforkoreanpatientswithhcvgenotypeibinfectionaretrospectivemultiinstitutionalstudy AT hongsookim efficacyandsafetyofdaclatasvirplusasunaprevirforkoreanpatientswithhcvgenotypeibinfectionaretrospectivemultiinstitutionalstudy AT taeheelee efficacyandsafetyofdaclatasvirplusasunaprevirforkoreanpatientswithhcvgenotypeibinfectionaretrospectivemultiinstitutionalstudy AT youngwookang efficacyandsafetyofdaclatasvirplusasunaprevirforkoreanpatientswithhcvgenotypeibinfectionaretrospectivemultiinstitutionalstudy AT seokhyunkim efficacyandsafetyofdaclatasvirplusasunaprevirforkoreanpatientswithhcvgenotypeibinfectionaretrospectivemultiinstitutionalstudy AT byungseoklee efficacyandsafetyofdaclatasvirplusasunaprevirforkoreanpatientswithhcvgenotypeibinfectionaretrospectivemultiinstitutionalstudy AT heebokchae efficacyandsafetyofdaclatasvirplusasunaprevirforkoreanpatientswithhcvgenotypeibinfectionaretrospectivemultiinstitutionalstudy |
_version_ |
1725302571650777088 |